NO20071921L - Fremgangsmater for behandling av epileptogenese og epilepsi - Google Patents

Fremgangsmater for behandling av epileptogenese og epilepsi

Info

Publication number
NO20071921L
NO20071921L NO20071921A NO20071921A NO20071921L NO 20071921 L NO20071921 L NO 20071921L NO 20071921 A NO20071921 A NO 20071921A NO 20071921 A NO20071921 A NO 20071921A NO 20071921 L NO20071921 L NO 20071921L
Authority
NO
Norway
Prior art keywords
group
phenyl
alkyl
epilepsy
methods
Prior art date
Application number
NO20071921A
Other languages
English (en)
Inventor
Boyu Zhao
Roy E Twyman
Robert Gordon
Yong Moon Choi
Gerald P Novak
Carlos R Plata-Ssalaman
H Steve White
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20071921L publication Critical patent/NO20071921L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Denne oppfinnelsen er rettet mot fremgangsmåter for forebygging, behandling, reversering, inhibering eller arrestering av epilepsi og epileptogenese i et emneå administrere til emnet med behov derav en terapeutisk effektiv mengde av en sammensetning valgt fra gruppen bestående av formel (I) og formel (II), eller et farmasøytisk aksepterbart salt eller en ester derav, hvori fenyl er substituert ved X med en til fem halogenatomer valgt fra gruppen bestående av fluor, klor, brom og jod; og, Ri, R, R3, R4, Rs og Rer uavhengig valgt fra gruppen bestående av hydrogen og C-Calkyl; hvori C-Calkyl er valgfritt substituert med fenyl (hvori fenyl er valgfritt substituert med substituentene uavhengig valgt fra gruppen bestående av halogen, Ci-C4 alkyl, C-Calkoksy, amino, nitro og cyano).
NO20071921A 2004-09-16 2007-04-16 Fremgangsmater for behandling av epileptogenese og epilepsi NO20071921L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61027604P 2004-09-16 2004-09-16
US69862505P 2005-07-12 2005-07-12
US70724205P 2005-08-11 2005-08-11
PCT/US2005/032861 WO2006033947A2 (en) 2004-09-16 2005-09-15 Use of 2-phenyl-1, 2-ethanediol- (di) carbamates for treating epileptogenesis and epilepsy

Publications (1)

Publication Number Publication Date
NO20071921L true NO20071921L (no) 2007-06-12

Family

ID=36087909

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071921A NO20071921L (no) 2004-09-16 2007-04-16 Fremgangsmater for behandling av epileptogenese og epilepsi

Country Status (22)

Country Link
US (2) US20060194873A1 (no)
JP (1) JP2008513466A (no)
KR (1) KR20070057939A (no)
CN (1) CN101056629B (no)
AT (1) ATE464044T1 (no)
AU (1) AU2005287174B2 (no)
BR (1) BRPI0515374A (no)
CA (1) CA2580640A1 (no)
CO (1) CO6382111A2 (no)
CR (1) CR9053A (no)
DE (1) DE602005020667D1 (no)
DK (1) DK1809273T3 (no)
EA (1) EA200700642A1 (no)
ES (1) ES2342185T3 (no)
HR (1) HRP20100304T1 (no)
IL (1) IL181910A0 (no)
MX (1) MX2007003278A (no)
NO (1) NO20071921L (no)
NZ (1) NZ553813A (no)
PT (1) PT1809273E (no)
RS (1) RS51269B (no)
WO (1) WO2006033947A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517407A (en) * 1999-08-10 2003-10-31 Uab Research Foundation Use of GABA agonists for treatment of spastic disorders, convulsions, and epilepsy
BRPI0516112A (pt) * 2004-10-15 2008-08-26 Janssen Pharmaceutica Nv métodos para neuroproteção
PE20070325A1 (es) * 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EA019757B1 (ru) 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
JP2010505856A (ja) * 2006-10-06 2010-02-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （ｓ）−（＋）−２−（２−クロロフェニル）−２−ヒドロキシ−エチルカルバメートの新規結晶
BRPI0718323A2 (pt) * 2006-10-31 2013-11-26 Janssen Pharmaceutica Nv Tratamento de transtornos invasivos do desenvolvimento.
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
MX353024B (es) 2011-12-27 2017-12-18 Bio Pharm Solutions Co Ltd Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
CN109939092B (zh) 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
CN105189451A (zh) * 2013-03-12 2015-12-23 比皮艾思药物研发有限公司 氨基甲酸苯酯化合物和包含该化合物的用于预防或治疗神经性毒气引起的疾病的组合物
WO2017150903A1 (en) 2016-02-29 2017-09-08 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
CN106053510A (zh) * 2016-05-16 2016-10-26 山东省分析测试中心 一种基于氢核磁共振快速测定普瑞巴林原料药纯度的方法
KR102421006B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도
US20230338295A1 (en) * 2020-08-06 2023-10-26 Sk Biopharmaceuticals Co., Ltd. Solid oral composition comprising carbamate compound, and preparation method therefor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US20010034365A1 (en) * 1996-01-16 2001-10-25 Choi Yong Moon Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
AU3304997A (en) * 1996-05-31 1998-01-05 Southern Illinois University Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation
DK1156798T3 (da) * 1999-02-09 2003-11-03 Univ Virginia Felbamat-afledte forbindelser
MXPA02001612A (es) * 1999-07-26 2003-10-14 Sk Corp Composiciones anti-convulsivas transnasales y procedimiento modular.
EP1383489B1 (en) * 2001-02-27 2007-05-09 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neurodegenerative disorders
US7122576B2 (en) * 2001-02-27 2006-10-17 Plata-Salaman Carlos R Carbamate compounds for use in preventing or treating bipolar disorder
ES2262801T3 (es) * 2001-02-27 2006-12-01 Ortho-Mcneil Pharmaceutical, Inc. Uso de un compuesto de carbamato para la prevencion o el tratamiento de trastorno bipolar.

Also Published As

Publication number Publication date
ES2342185T3 (es) 2010-07-02
WO2006033947A2 (en) 2006-03-30
CR9053A (es) 2009-10-30
HK1105583A1 (en) 2008-02-22
CN101056629A (zh) 2007-10-17
PT1809273E (pt) 2010-05-10
MX2007003278A (es) 2007-10-08
JP2008513466A (ja) 2008-05-01
CN101056629B (zh) 2012-01-11
AU2005287174B2 (en) 2012-01-12
EA200700642A1 (ru) 2007-10-26
CO6382111A2 (es) 2012-02-15
HRP20100304T1 (hr) 2010-09-30
DE602005020667D1 (de) 2010-05-27
WO2006033947A3 (en) 2006-06-29
IL181910A0 (en) 2007-07-04
US20060194873A1 (en) 2006-08-31
NZ553813A (en) 2010-09-30
ATE464044T1 (de) 2010-04-15
US20110152362A1 (en) 2011-06-23
DK1809273T3 (da) 2010-08-02
BRPI0515374A (pt) 2008-07-22
AU2005287174A1 (en) 2006-03-30
KR20070057939A (ko) 2007-06-07
RS51269B (sr) 2010-12-31
CA2580640A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
NO20071921L (no) Fremgangsmater for behandling av epileptogenese og epilepsi
NO20080877L (no) Fremgangsmater for behandling av substansrelaterte forstyrrelser
YU67703A (sh) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
MY138156A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
WO2007008562A3 (en) Carbamate compounds for use in treating neurodegenerative disorders
IL157590A0 (en) Carbamate compounds for use in preventing or treating bipolar disorder
TW200744575A (en) Methods of treating epileptogenesis
IL157594A0 (en) Carbamate compounds for use in preventing or treating anxiety disorders
MX2009004553A (es) Metodos para el tratamiento de trastornos cocleares y vestibulares.
EA200700871A1 (ru) Способы нейропротекции
TW200701978A (en) Methods of treating epileptogenesis and epilepsy
IL159847A0 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders
CY1110672T1 (el) Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης
MY149385A (en) Methods for treating substance-related disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application